Modern aspects of antithrombotic treatment: An introduction

Journal of Heart Valve Disease

Volumn 13, Issue 3, 2004, Pages 314-318

  Horstkotte, Dieter ^a   Piper, Cornelia ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

CORONARY ARTERY THROMBOSIS; DRUG COMBINATION; EMBOLISM; FIBRINOLYTIC THERAPY; HUMAN; REVIEW; VALVULAR HEART DISEASE;

ANTICOAGULANTS; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; EMBOLISM; HEART VALVE DISEASES; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOLYTIC THERAPY; WARFARIN;

EID: 5144225079     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Horstkotte D, Schulte HD, Bircks W, Strauer BE. Quality of life and prognosis following heart valve replacement. In: Walter PJ (ed.), Quality of life after open heart surgery. Kluwer, Dordrecht 1992:19-35
2. Piper C, Hering D, Horstkotte D. Prosthetic valve thrombosis: Predisposition and diagnosis. Eur Heart J Suppl 2001;3(Suppl. Q):Q16-Q22
3. Caro JJ. Migliaccio-Walli K, O'Brian JA. The cost of treating heart valve-related complications. J Heart Valve Dis 1996;5:122-127
4. Harris AW, Levine SA. Cerebral embolism and mitral stenosis. Ann Intern Med 1941;15:637-641
5. Willius FA. Embolic manifestation of heart disease. J Iowa St Med Soc 1926;16:437-441
6. Horstkotte D, Hering D, Faber L, Piper C. Cardiac morphology and physiology predisposing to thrombus formation. Eur Heart J Suppl 2001;3(Suppl. Q):Q8-Qll
7. Horstkotte D. Arrhythmias in the natural history of mitral stenosis. Acta Cardiol 1992;47:105-113
8. Horstkotte D, Aul C, Seipel L, et al. Effect of valve type and valve function on chronic intravascular hemolysis after alloprosthetic mitral and aortic valve replacement. Z Kardiol 1983;72:119-131
9. Scharf RE, Giers G. Molecular mechanisms and indicators of thrombogenesis after heart valve replacement. Z Kardiol 1998;87(Suppl. 4):7-19
10. Brummel KE, Paradis SG, Branda RF, Mann KG. Oral anticoagulation thresholds. Circulation 2001;104:2311-2317
11. Horstkotte D, Scharf RE, Schultheiß HP. Intracardiac thrombosis: Patient-related and device-related factors. J Heart Valve Dis 1995;4:114-120
12. Butchart EG, Ionescu A, Payne N, Giddings J, Grunkemeier GL, Fraser AG. A new scoring system to determine thromboembolic risk after heart valve replacement. Circulation 2003;108(Suppl. II): II-68-II-74
13. Björk VO, Henze A. Management of thromboembolism after aortic valve replacement with the Björk-Shiley tilting disc valve. Scand J Thorac Cardiovasc Surg 1975;9:183-191
14. Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart valve replacement. N Engl J Med 1993;329:524-579
15. Meschengieser SS, Fondevila CG, Frontroth J, Santarelli MT, Lazzari MA. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: A randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg 1997;113:910-916
16. Massel D, Little SH. Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: A meta-analysis. J Am Coll Cardiol 2001;37:569-578
17. Edmunds LH, Jr., Clark RE, Cohn LH, et al. Guidelines for reporting morbidity and mortality after cardiac valvular operations. J Thorac Cardiovasc Surg 1996;112:708-711
18. Horstkotte D. Problems with complication rate analysis. J Thorac Cardiovasc Surg 2003;126:1668-1670
19. Horstkotte D, Schulte HD, Bircks W, Strauer BE. Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 1994;107:1136-1145
20. Horstkotte D, Bergemann R, Althaus U, et al. German Experience with Low Intensity Anticoagulation (GELIA): Protocol of a multi-center randomized prospective study with the St. Jude Medical valve. J Heart Valve Dis 1993;2:411-419
21. Karnofsky DA, Burchenai JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed.), Symposium held at New York Academy of Medicine. Columbia University Press 1949:191-205
22. Bergemann R, Hillenbach C. Addendum. Eur Heart J Suppl 2001;3(Suppl. Q):Q78-Q79
23. Bodnar E, Horstkotte D. Potential flaws in the assessment of minor cerebrovascular events after heart valve replacement. J Heart Valve Dis 1993;2:287-290
24. Horstkotte D, Trampisch HJ. Langzeitbeobachtungen nach Herzklappenersatz. Z Kardiol 1986;75:641-645
25. Oden A, Fahlen M. Oral anticoagulation and risk of death: A medical record linkage study. Br Med J 2002;325:1073-1075
26. Piper C, Horstkotte D. State of the Art-Anticoagulation Management. J Heart Valve Dis 2004 (in press);13(Suppl I):73-77
27. Bernardo A, Völler H. Leitlinien " Gerinnungsselbstmanagement". Dtsch Med Wschr 2001;126:346-351
28. Zerback R, Horstkotte D. Patient self-monitoring in follow-up of long-term anticoagulant therapy. Z Kardiol 1998;87(Suppl. 4):68-74
29. Cromheecke M, Colly L, de Mol B, et al. Oral anti-coagulation self-management and management by a specialist anticoagulation clinic: A randomised cross-over comparison. Lancet 2000;356:97-102
30. Hasenkam JM, Kimose HH, Knudsen L, et al. Self-management of oral anticoagulant therapy after heart valve replacement. Eur J Cardiothorac Surg 1997;11:935-942
31. Ansell JE, Hughes R. Evolving models of warfarin management: Anticoagulation clinics, patient self-monitoring, and patient self-management. Am Heart J 1996;132:1096-1100
32. Koertke H, Minami K, Boethig D, et al. INR self-management permits lower anticoagulation levels after mechanical heart valve replacement. Circulation 2003;108(Suppl. I): II-75-II-78
33. Huth C, Friedl A, Rost A for the GELIA Study Investigator Group. Intensity of oral anticoagulation after implantation of St. Jude Medical aortic prosthesis: Analysis of the GELIA database (GELIA 4). Eur Heart J Suppl 2001;3(Suppl. Q):Q33-Q38
34. Pruefer D, Dahm M, Dohmen, Horstkotte D, Bergemann R, Oelert H. Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: Lessons learned from GELIA (GELIA 5) Eur Heart J Suppl 2001;3(Suppl. Q):Q33-Q38
35. Horstkotte D, Piper C, Wiemer W. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis 1998;5:S19-S24
36. Casselmann FP, Bots ML, Van Lommel W, Knaepen PJ, Lensen R, Vermeulen FEE. Repeated thromboembolic and bleeding events after mechanical aortic valve replacement. Ann Thorac Surg 2001;71:1172-1180